Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 144.45% | -8.43% | 7.01% | -3.84% | 46.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.44% | -17.99% | 11.65% | 0.57% | 31.24% |
| Operating Income | 32.11% | 17.99% | -11.65% | 61.87% | -31.24% |
| Income Before Tax | 21.94% | 27.61% | 22.23% | 116.12% | -10.35% |
| Income Tax Expenses | -51.85% | -187.10% | 143.97% | 32.41% | 62.50% |
| Earnings from Continuing Operations | 22.10% | 27.70% | 21.58% | 115.87% | -10.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -- | -- | -34.88% | 69.23% |
| Net Income | 22.07% | 27.68% | 21.55% | 115.93% | -10.82% |
| EBIT | 32.11% | 17.99% | -11.65% | 61.87% | -31.24% |
| EBITDA | 32.24% | 18.05% | -11.75% | 62.16% | -31.50% |
| EPS Basic | 22.55% | 28.19% | 32.87% | 113.31% | 9.05% |
| Normalized Basic EPS | -9.19% | 28.09% | 17.45% | 113.56% | 8.82% |
| EPS Diluted | 22.55% | 28.19% | 32.87% | 113.08% | 9.05% |
| Normalized Diluted EPS | -9.19% | 28.09% | 17.45% | 113.50% | 8.82% |
| Average Basic Shares Outstanding | 0.62% | 0.71% | 16.86% | 19.60% | 21.84% |
| Average Diluted Shares Outstanding | 0.62% | 0.71% | 16.86% | 20.10% | 21.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |